Grufity logoGrufity logo

REGN

736.23USD+0.87(+0.12%)Market Closed

Regeneron Pharmaceuticals Inc

Market Summary

USD736.23+0.87Market Closed
0.12%

REGN Alerts

REGN Stock Price

RSI Chart

Valuation

Market Cap

81.0B

Price/Earnings

14.24

Price/Sales

5.69

Price/Cashflow

9.58

MarketCap/EBT

12.77

Price/Sales

Profitability

EBT Margin

44.59%

Return on Equity

27.49%

Return on Assets

20.9%

Fundamentals

Revenue

Revenue (TTM)

14.2B

Revenue Y/Y

-44.4%

Revenue Q/Q

-3.64%

Earnings

Earnings (TTM)

5.7B

Earnings Y/Y

-72.5%

Earnings Q/Q

-12.47%

Price Action

52 Week Range

538.01769.63
(Low)(High)

Last 7 days

-0.1%

Last 30 days

0.3%

Last 90 days

23.5%

Trailing 12 Months

13.6%

Financial Health

Current Ratio

5.12

Debt/Equity

0.07

Debt/Cashflow

5.59

Investor Care

Shares Dilution (1Y)

2.76%

Diluted EPS (TTM)

50.09

Peers (Alternatives to Regeneron Pharmaceuticals)

View All Peers In Detail
NameMkt Capsorted ascendingRevenuePrice %, 1MReturns, 1YP/EP/SRev 1-YrInc 1-Yr
LARGE-CAP
261.0B
57.8B
4.66% 39.76%
20.65
4.55
4.80% 77.95%
224.2B
1.2B
2.35% -50.22%
-111.81
209.81
17.64% -65.25%
81.0B
14.2B
0.31% 13.58%
14.24
5.69
14.88% -8.36%
80.6B
8.7B
0.58% 68.05%
24.61
9.26
22.03% 50.41%
25.2B
960.9M
5.82% 12.67%
-21.28
26.18
28.24% -41.08%
10.6B
1.9B
17.73% 33.91%
16.75
5.91
12.37% 52.98%
10.1B
876.0M
0.23% 41.48%
-19.93
12.09
35.70% -47.34%
MID-CAP
4.1B
-
-5.94% -0.54%
-18.85
63.29
26.15% -23.38%
3.8B
-
41.63% -30.16%
-5.86
917.1
-74.20% -52.72%
3.2B
272.3M
-10.09% -56.96%
-4.51
13.74
-18.36% -74.56%
2.9B
334.3M
-10.63% -53.96%
-5.64
8.54
-6.98% -43.97%
SMALL-CAP
1.5B
191.8M
18.84% 129.95%
26.77
8.56
43.59% 60.82%
1.3B
504.0K
-5.86% -21.13%
-4.91
2.5K
-66.53% -10.64%
306.1M
66.9M
28.14% -69.87%
-1.4
4.57
-43.57% -69.06%
16.0M
-
-12.01% -87.39%
-0.46
19.11
-77.61% 5.14%

Financials for Regeneron Pharmaceuticals

Income Statement (Last 12 Months)
(In Millions)
Description(%) Q/Q2022Q22022Q12021Q42021Q32021Q2
Revenue-13.8%14,22716,50816,07213,54312,384
  S&GA Expenses3.3%1,9311,8691,8251,5691,451
  R&D Expenses2.7%3,0893,0092,9082,8672,886
Earnings Before Taxes-30.5%6,3449,1349,3268,0477,229
Net Income-28.3%5,6877,9348,0756,9966,205
Balance Sheet
(In Millions)
Description(%) Q/Q2022Q22022Q12021Q42021Q32021Q2
Assets3.3%27,20626,34925,43523,67221,486
  Current Assets8.6%15,53014,30614,01513,77513,338
    Cash Equivalents1.5%3,3953,3462,8863,4322,072
  Inventory11.4%2,2191,9921,9512,0541,984
  Net PPE2.3%3,6383,5563,4823,3963,359
Liabilities1.3%6,5186,4346,6666,4146,359
  Current Liabilities0.9%3,0343,0083,9333,7153,732
  Long Term Debt-10.3%1,5131,6861,8871,8911,868
    LT Debt, Non Current0.0%1,9811,9801,9801,9801,979
Shareholder's Equity3.9%20,68819,91518,76917,25815,127
  Retained Earnings4.3%20,79419,94218,96816,73915,107
  Additional Paid-In Capital4.2%9,1208,7548,0887,9197,226
Shares Outstanding1.0%108107106105-
Float-57,065----
* denotes actual numbers (not divided by Millions)
Cashflow (Last 12 Months)
(In Millions)
Description(%) Q/Q2022Q22022Q12021Q42021Q32021Q2
Cashflow From Operations-0.7%8,4528,5157,0815,9402,272
  Share Based Compensation2.2%652638602535499
Cashflow From Investing-8.9%-6,570.70-6,031.00-5,384.70-3,677.00-2,014.00
Cashflow From Financing3.0%-557.60-574.70-1,005.80-404.50-177.90
  Buy Backs6.2%1,8091,7041,6451,1671,077

Risks

What is the probability of a big loss on REGN?

71.2%


Probability that Regeneron Pharmaceuticals stock will be more than 20% underwater in next one year

39.6%


Probability that Regeneron Pharmaceuticals stock will be more than 30% underwater in next one year.

6.5%


Probability that Regeneron Pharmaceuticals stock will be more than 40% underwater in next one year.
*Calculated based on probability distribution of losses observed in actual data in the last 5 years.

How does REGN drawdown profile look like?

Y-axis is the maximum loss one would have experienced if Regeneron Pharmaceuticals was unfortunately bought at previous high price.

Returns

Cumulative Returns on REGN

15.5%


10-Year Cumulative Returns

3.9%


7-Year Cumulative Returns

13.9%


5-Year Cumulative Returns

26.5%


3-Year Cumulative Returns

What are the long-term rolling returns for REGN?

FIve years rolling returns for Regeneron Pharmaceuticals.

Which funds bought or sold REGN recently?

View All Details
Datesorted ascendingFund NameType% Chg$ Change$ Held% Portfolio
2022-11-23
Eagle Bay Advisors LLC
REDUCED
-5.88
5,705
66,000
0.04%
2022-11-23
Toroso Investments, LLC
REDUCED
-14.27
-4,000
4,251,000
0.18%
2022-11-22
Capital Impact Advisors, LLC
-
-
9,000
308,000
0.31%
2022-11-22
TEACHERS RETIREMENT SYSTEM OF THE STATE OF KENTUCKY
NEW
-
16,532,000
16,532,000
0.19%
2022-11-22
Seaport Global Advisors, LLC
-
-
65,000
329,000
1.34%
2022-11-22
CVA Family Office, LLC
-
-
23,000
79,000
0.02%
2022-11-22
B. Riley Wealth Advisors, Inc.
ADDED
2.24
187,000
1,162,000
0.04%
2022-11-22
IHT Wealth Management, LLC
-
-
222,000
448,000
0.03%
2022-11-21
Parallax Volatility Advisers, L.P.
REDUCED
-98.13
-1,851,000
41,000
-%
2022-11-21
CALIFORNIA STATE TEACHERS RETIREMENT SYSTEM
-
-
17,433,000
123,907,000
0.21%

1–10 of 42

Latest Funds Activity

Are funds buying REGN calls or puts?
Are funds bullish or bearish(Calls - Puts)?
No. of funds that own REGN

Regeneron Pharmaceuticals News

Seeking Alpha

SPGP: 'GARP' ETF Has Opposite Strategy Of ARK Funds (NYSEARCA:SPGP).13 hours ago

REGN Fair Value

Recent SEC filings of Regeneron Pharmaceuticals

View All Filings
Date Filed Form Type Document
Nov 16, 2022
4
Insider Trading
Nov 10, 2022
4
Insider Trading
Nov 08, 2022
4
Insider Trading
Nov 07, 2022
4
Insider Trading
Nov 03, 2022
10-Q
Quarterly Report
Nov 03, 2022
4
Insider Trading
Nov 03, 2022
8-K
Current Report
Nov 02, 2022
4
Insider Trading
Nov 02, 2022
4
Insider Trading
Oct 18, 2022
4
Insider Trading

Latest Insider Trading transactions for REGN

Filter Transactions
Datesorted ascendingNameBuy/Sell$ ValueAvg. Price# SharesTitle
2022-11-15
MURPHY ANDREW J
SOLD
-2,707,470
727.814
-3,720
EVP Research
2022-11-14
MURPHY ANDREW J
GIFTED
-
-
-1,360
EVP Research
2022-11-14
MURPHY ANDREW J
SOLD FOR TAXES
-4,684,880
746
-6,280
EVP Research
2022-11-14
MURPHY ANDREW J
ACQUIRED
1,791,300
179.13
10,000
EVP Research
2022-11-08
BROWN MICHAEL S
SOLD
-3,016,950
755.18
-3,995
-
2022-11-08
BROWN MICHAEL S
SOLD
-374,245
748.49
-500
-
2022-11-08
BROWN MICHAEL S
ACQUIRED
1,664,400
416.62
3,995
-
2022-11-07
Van Plew Daniel P
SOLD
-5,878,260
745.405
-7,886
EVP & General Mgr, Industrial
2022-11-04
McCourt Marion
ACQUIRED
372,460
372.46
1,000
EVP Commercial
2022-11-04
Van Plew Daniel P
ACQUIRED
12,985,300
381.92
34,000
EVP & General Mgr, Industrial

1–10 of 50

Leonard S. Schleifer
10400
Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; and diabetic retinopathy, as well as macular edema following retinal vein occlusion, including macular edema following central retinal vein occlusion and macular edema following branch retinal vein occlusion. It also provides Dupixent injection to treat atopic dermatitis and asthma in adults and pediatrics; Libtayo injection to treat metastatic or locally advanced cutaneous squamous cell carcinoma;Praluent injection for heterozygous familial hypercholesterolemia or clinical atherosclerotic cardiovascular disease in adults; REGEN-COV for covid-19; and Kevzara solution for treating rheumatoid arthritis in adults. In addition, the company offers Inmazeb injection for infection caused by Zaire ebolavirus; ARCALYST injection for cryopyrin-associated periodic syndromes, including familial cold auto-inflammatory syndrome and muckle-wells syndrome; and ZALTRAP injection for intravenous infusion to treat metastatic colorectal cancer; and develops product candidates for treating patients with eye, allergic and inflammatory, cardiovascular and metabolic, infectious, and rare diseases; and cancer, pain, and hematologic conditions. It has collaboration and license agreements with Sanofi; Bayer; Teva Pharmaceutical Industries Ltd.; Mitsubishi Tanabe Pharma Corporation; Alnylam Pharmaceuticals, Inc.; Roche Pharmaceuticals; and Kiniksa Pharmaceuticals, Ltd., as well as has an agreement with the U.S. Department of Health and Human Services, as well as with Zai Lab Limited; Intellia Therapeutics, Inc.; Biomedical Advanced Research Development Authority; and AstraZeneca PLC. The company was incorporated in 1988 and is headquartered in Tarrytown, New York.

REGN Income Statement

2022-09-30
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE INCOME (Unaudited) - USD ($)
shares in Millions, $ in Millions
3 Months Ended9 Months Ended
Sep. 30, 2022
Sep. 30, 2021
Sep. 30, 2022
Sep. 30, 2021
Revenues:    
Revenues$ 2,936.2$ 3,452.8$ 8,758.5$ 11,120.0
Expenses:    
Research and development911.3665.42,549.42,122.5
Acquired in-process research and development0.00.0225.10.0
Selling, general, and administrative529.1445.01,455.41,265.3
Other operating (income) expense, net(45.7)42.0(83.3)(29.8)
Costs and expenses, total1,712.51,605.65,166.44,812.9
Income from operations1,223.71,847.23,592.16,307.1
Other income (expense):    
Other income (expense), net301.4(16.4)(16.0)558.5
Interest expense(15.3)(14.2)(42.0)(43.2)
Total other income (expense)286.1(30.6)(58.0)515.3
Income before income taxes1,509.81,816.63,534.16,822.4
Income tax expense194.1184.4392.8976.1
Net income$ 1,315.7$ 1,632.2$ 3,141.3$ 5,846.3
Net income per share - basic (in dollars per share)$ 12.31$ 15.37$ 29.30$ 55.42
Net income per share - diluted (in dollars per share)$ 11.66$ 14.33$ 27.73$ 52.29
Weighted average shares outstanding - basic (in shares)106.9106.2107.2105.5
Weighted average shares outstanding - diluted (in shares)112.8113.9113.3111.8
Statements of Comprehensive Income    
Net income$ 1,315.7$ 1,632.2$ 3,141.3$ 5,846.3
Other comprehensive income (loss), net of tax:    
Unrealized loss on debt securities(51.3)(6.4)(249.9)(20.5)
Unrealized gain on cash flow hedges0.00.21.00.7
Comprehensive income1,264.41,626.02,892.45,826.5
Net product sales    
Revenues:    
Revenues1,801.42,279.95,194.48,142.0
Expenses:    
Cost of goods, collaboration and contract manufacturing141.3238.8497.8961.4
Collaboration revenue    
Revenues:    
Revenues1,050.61,073.93,326.72,783.0
Other revenue    
Revenues:    
Revenues84.299.0237.4195.0
Cost of collaboration and contract manufacturing    
Expenses:    
Cost of goods, collaboration and contract manufacturing$ 176.5$ 214.4$ 522.0$ 493.5

REGN Balance Sheet

2022-09-30
CONDENSED CONSOLIDATED BALANCE SHEETS (Unaudited) - USD ($)
$ in Millions
Sep. 30, 2022
Dec. 31, 2021
Current assets:  
Cash and cash equivalents$ 3,491.3$ 2,885.6
Marketable securities3,530.42,809.1
Accounts receivable, net5,548.36,036.5
Inventories2,412.21,951.3
Prepaid expenses and other current assets446.4332.4
Total current assets15,428.614,014.9
Marketable securities5,968.66,838.0
Property, plant, and equipment, net3,704.23,482.2
Intangible assets, net804.16.7
Deferred tax assets1,452.1876.9
Other noncurrent assets320.2216.1
Total assets27,677.825,434.8
Current liabilities:  
Accounts payable535.6564.0
Accrued expenses and other current liabilities1,796.42,206.8
Finance lease liabilities0.0719.7
Deferred revenue547.2442.0
Total current liabilities2,879.23,932.5
Long-term debt1,981.11,980.0
Finance lease liabilities720.00.0
Deferred revenue60.173.3
Other noncurrent liabilities598.6680.2
Total liabilities6,239.06,666.0
Stockholders' equity:  
Preferred Stock, par value $.01 per share; 30.0 shares authorized; issued and outstanding - none0.00.0
Additional paid-in capital9,518.28,087.5
Retained earnings22,109.618,968.3
Accumulated other comprehensive loss(275.1)(26.2)
Treasury Stock, at cost; 22.0 shares in 2022 and 19.4 shares in 2021(9,914.0)(8,260.9)
Total stockholders' equity21,438.818,768.8
Total liabilities and stockholders' equity27,677.825,434.8
Class A Stock  
Stockholders' equity:  
Common stock0.00.0
Common Stock  
Stockholders' equity:  
Common stock$ 0.1$ 0.1